About Primary Sjogren Syndrome
Primary Sjogren Syndrome is a chronic systemic autoimmune disease driven by lymphocytic infiltration of exocrine glands, particularly salivary and lacrimal glands, causing the hallmark features of dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia), with frequent extraglandular manifestations affecting joints, lung, kidney, peripheral nervous system, and skin. Serological hallmarks include anti-Ro/SSA and anti-La/SSB autoantibodies, elevated polyclonal immunoglobulins, and cryoglobulins, with a markedly increased risk of non-Hodgkin B-cell lymphoma compared to the general population. Targeted biologics including belimumab, ianalumab, and CD40 pathway inhibitors are under active investigation in clinical trials.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Primary Sjogren Syndrome trials.
Fulfillment of 2016 ACR/EULAR classification criteria (score ≥4) with positive lip biopsy or anti-Ro/SSA serology is typically required; gather biopsy pathology, salivary flow measurements, and Schirmer test results
ESSDAI score (disease activity) and ESSPRI score (patient-reported symptoms) are the standard outcome measures; baseline scores are often used as eligibility thresholds — ask your rheumatologist to calculate these at your next visit
Lymphoma history is a common exclusion criterion; if you have had cryoglobulinemic vasculitis or lymphoproliferative complications, disclose these at screening as they may affect eligibility differently across trials
Patient Resources
Find recruiting Primary Sjogren Syndrome trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Primary Sjogren Syndrome. Updated daily.